Member Info for sadoldgit

Not sure if justifies an RNS. As it is a compound being patented for treatment of AML this would surely indicate that this would be to protect Aurora + FLT 3. This is very intriguing. It adds value to FLT but it as has been put on back burner, to concentrate on Tyk2 developments.
It does raise the question of what Sareum's plans are for FLt +3. The problem they had was large scale production of the compound suitable to be taken orally. Not too dissimilar from that encountered with Tyk 2 in manufacturing compounds in sufficient amounts to enable MT D to be established prior to stage 1 clinical.trials.

Would not like to put a price on worth but AML current treatments not up to much.
REgards

Not sure if justifies an RNS. As it is a compound being patented for treatment of AML this would surely indicate that this would be to protect Aurora + FLT 3. This is very intriguing. It adds value to FLT but it as has been put on back burner, to concentrate on Tyk2 developments.
It does raise the question of what Sareum's plans are for FLt +3. The problem they had was large scale production of the compound suitable to be taken orally. Not too dissimilar from that encountered with Tyk 2 in manufacturing compounds in sufficient amounts to enable MT D to be established prior to stage 1 clinical.trials.

Would not like to put a price on worth but AML current treatments not up to much.
REgards

C007. You are welcome lad. Have much to post but must break it down so posters here understand easily.
Many people that have claimed to be here many years I find are either bull.....s or have no idea in what they are invested in. The SP has waned. Traders will move to nigh guaranteed returns due to the war and increase in energy prices. On no imminent expectation of news historically the MC has fallen.

SP in my belief has bottomed. Where traders have left the true investor has invested. Sooner or later the SP will rise. Hence my comment regarding buys and sells on a previous post

Regards
PS at present have an avid Celtic supporter from Largs who I have known for years lodge with us.

C79. Great posts as us usual from you sir, you can clog up the board all day long as far as I am concerned. Always a pleasure to read.
Worthwhile having a quick butchers at below as an overview of competitors current inhibitors.
www.verywellhealth.com/jak-inhibitors-4706526

Look at the second second generation Rinvoq ( Upradactinib) looks good in what it can treat. then look up side effects.

https://www.drugs.com/mtm/upadacitinib.html

' Upadacitinib is a second generation Janus kinase inhibitor that is selective for the JAK1 subtype of this enzyme over the JAK2 (74-fold), JAK3 (58-fold) and tyrosine kinase 2 subtypes.' No Tyk2 inhibition!

With regards to an effective treatment in an indication whether psoriasis , RA. SLE or whatever indication and importantly the dosages which are administered, it is limited by the amount of toxicity leading to adverse side effects. These are just not limited to infection which is very much associated with JAK2 and especially Jak3 but also other life threatening conditions.

Now bare in mind, and I am sure you are aware that the greater the selectivity of an inhibitor the lesser the adverse effects that will be encountered, hence this enables higher dosages to be administered in treating an indication , enabling far more dosage than may be required.

Worthy of mention is that over 30 times dosage treatment were completed in an effort to reach am MTD with no indication of this being the limit.

I will further add
'Upon receptor activation, Tyk2, in combination with either JAK1 or JAK2, phosphorylates the intracellular receptor domains, which in turn recruit specific STAT proteins. The STATs subsequently are phosphorylated, causing disassociation from the receptor and the formation of STAT dimers that translocate into the nucleus and trigger gene transcription processes leading to an inflammatory response. Studies in Tyk2-deficient mice have suggested that Tyk2 is required for IL-23, IL-12, and Type I interferon signaling, but not IL-6 and IL-10 responses.'
In another report stated that in mice that IL-6 and IL-10 is not dependant on Tyk2

Now recently and very importantly is added the below:-

157 In humans, only two patients lacking the Tyk2 protein have been reported, and only one of these patients was thoroughly studied for defective cytokine responses.158 These studies indicated a potentially broader role of Tyk2 signaling in humans versus mouse since IL-6 and IL-10 pathways also were found to be Tyk2-dependent.

Although in investigation murine is used as has a much faster metabolism and cell replication rate, we are not mice.

Regards and the crate is opened

I believe we are on to a winner.

Hi C79. slightly off topic here with your post.

SRA737+%2B+IO%2F+gemcetibine&qs=n&form=QBRE&sp=-1&ghc=1&pq=sra737+%2B+io%2F+gemcetibine&sc=0-24&sk=&cvid=382CAB5903794102A84DAE1CFDC2F4A8
Interesting data regards SRA737 in combo. Circa 2018 so getting on a bit, but take a look at figure 7 with Sra737 in combo with anti PD-L1 in 3 in 7 day and 5 in 7 days of vehicle tumour inhibition and reduction. Sierra sitting on a goldmine me thinks.

Hi MKD. I am of the opinion that many of the shown as sells are actually buys. Not all but many.
SP spread going from 115 to 125 then, 120 to 125 in a matter of a few seconds.
If we also take into account that 'shown sells' far outweigh 'shown buys'

2 trades at 16k a few seconds apart and 2 trades at 10.7 k a few seconds apart. Historically this would result in a fall in the SP.
Strange forces at work.
Regards.

Mention of CHK1 by Sierra, nothing big.
https://www.sierraoncology.com/chk1/

Am Ok thankyou S79.
Working 12 hrs, 12 on and two off at the moment on nights. Busy and tiring to say the least. Not get much time to read here and contribute until I have weekend off.

Our inhibitors along with the patent protections and quality of formulation ought to give us the edge on all else at the moment.

There exists a difference in a CEO who genuinely wants to create a treatment for cancers and to the benefit to the human race as opposed to A CEO who wants his KPI's and targets met to satisfy shareholders and himself. The latter is full of flaws and is it any surprise that their are so many late stage failures.

Regards

I will add that whilst Tyk2 has and is showing much potential, the potential can only be fully realised paired with another Jak as Jaks work best in pairs. Tyk 2 more selective than Jak2 hence why bother with Tyk2 and Jak2. Tyk 2 not compatible with Jak3. Jak1 is compatible with Tyk 2 and with regards to toxicity is minimised due to an optimum addition of. Even better when molecular formulation through crystallisation of a compound can obtain 100% purity.

Regards

Good afternoon Citizen79. FWIIW my opinion is that whilst TYK2 has much potential it is interesting to note that that a TYK2 from one of our competitors did not cut the mustard with regards to Inflammatory bowel disease and I have an inkling that this is due to having no Jak1. Jak 1 and Tyk 2 together are required for the four sub units of IL-10 essential for some but not all indications. Tyk 2 cannot cut it alone and neither can Tyk 2.

https://investors.bms.com/iframes/press-releases/press-release-details/2021/Bristol-Myers-Squibb-Provides-Update-on-Phase-2-Study-of-Deucravacitinib-in-Patients-With-Moderate-to-Severe-Ulcerative-Colitis/default.aspx

Regards

Good afternoon Potnak, agree whole heartedly on what you posted. It has been confirmed the tox results are good. On going discussions been ongoing for an eternity with interested parties. 1801 and 1802 we are in control of, unfortunately SRA737 we are not.
My opinion is a JV or license of some sort with SDC1801. Covid 19 far from over but how the hell do you incorporate that into a price for on license? JV you can split, an on license is down to speculation with regards covid 19. However, we have many more indications prior to the Covid 19 scene as primarily it is an immunotherapy treatment.

Regards

Seawolf. tell me the options that Sareum had. Sareum were and still are in the minority. The fault lies with the CPF.
Sierra did well for first 3 years then pulled and diverted all resources into Momo.

My opinion for what it is worth is that the new negotiated agreement should return the original 7 million dollar milestone payment as they have done little to nothing in nigh 3 years.
They have been given enough leeway.

With all do respect Seawolf very little to do with Sareum in negotiations as they only have 27.5% interest.
Sierra had trialled and developed 737 from 2016 to mid 2019. In effect 3 years they have stuck 737 on the back burner. Combination of LDG and 737 investigations were done by Sareum in partnership with ICR prior to on licensing to Sierra if memory serves me correct.

I am very certain that although Sareum had very little sway in agreements they are well aware of the pitfalls of becoming involved in companies with limited financial clout to maintain their obligations.

Regards

Good post as usual from you Citizen 79. I would highlight the timing regards EP2634185. A fairly recent spread from sareum as evidently after patent grant by European Patent Office, circa 6 months ago.
You can also google the EP2634185 which will give indications for our compound SDC1801. It is indeed complex.
I will try and find the original patent description thread pertaining to list of indications relevant to our compounds and post later.

Regards

Regards

Interesting to note that they have now released the results. Where they are taking it is anyones guess.
I would suggest that by releasing the results it is a very vain attempt to show they are still in throws of development. Taken over two years from trial end which is dragging their heels to say the least.
It may well be they have been put under pressure by CPF. Use it or lose it so as to speak. At the same time this is not going to be something they would release as news.
737 extremely promising in cobo but spending months and months on end looking for non dilutive options to raise funds for development and months on the designing of new combination trials just does not cut the mustard.

Soon we will be into April and Sierra just cannot continue to kick the proverbial can down the road indefinitely.

Regards

Brilliant news notalot. I am extremely pleased for you. It must be a monumental weight taken off of your shoulders.

Regards

Tight spread up a couple of % to induce sells then into the red again l think. Becoming a regular pattern with PH.

ndr, they have not had the resources since July 2019. After 12 months of nothing then ceate a further delay by the claimed ' we are exploring options' 18 months later and now we are planning the design of new trials.

Until momo goes there will be very little development by Sierra in 737. In addition Sierra will become liable for the 180 odd million dollars to pay Gilead in milestone payments should it reach commercialisation.

Sierra have raised further funding but absolutely no indication that they will be spending on SRA737 in very near future.

Regards

Graking,
Stringent measures are put in place to protect the volunteers involved in dose escalation trials
Do you have any idea of how high they will go in dose limitation trials? It is true to an extent that it can be looked upon that the higher the dose that can be taken then the more compound they can administer with the idea being the greater the effect.

Dose escalation is done fir one reason only and that is to identify dosages that can be administered without undue cause for concern. It gives the medical profession parameters to work within.

Sooner or later a maximum safe dose without unacceptable side affects will be established, which is likely to be many times more than the current envisaged treatment levels.

If we take Covid 19 for example, is there a set dosing regime? We do know that cytokine control is dose dependant and in the instance of SDC 1801 there was no increase in viral load. If we look at a middle eastern respiratory distress syndrome illnesses then the dose required to dave lives is
likely to be much more than Covid 19 Deltacron.

Regards

K bundy. We have taken aboard about the best market cap and share price killer in the form of Peel Hunt. Just look at their performance. Not just here but other companies.

A week ago or so just after consolidation that bought the SP down to just under 2p in old money. Traders climb aboard. They are there to.make a profit after all. When the price goes up on some good news they sell thus pulling the SP down with it. It is Peel Hunts transparent tactic. This was after they pulled the market cap down by around 100 million in a day when they first come aboard. They want the shares to go to from investor to trader. Simple far easier to control. Of course the other benefit to PH is the amount of trades carried out at such times of negative volatility.

What you reckon the cause of a 4% at this moment in time us all about.

Regards